Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2020 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
TARS on Nasdaq
Shares outstanding
42,450,857
Price per share
$65.71
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
44,046,610
Total reported value
$3,606,025,781
% of total 13F portfolios
0%
Share change
-1,683,272
Value change
-$100,586,536
Number of holders
243
Price from insider filings
$65.71
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
RTW INVESTMENTS, LP 8.1% $134,159,372 3,424,180 RTW Investments, LP 30 Jun 2025
BlackRock, Inc. 7.4% $153,770,784 3,092,735 BlackRock, Inc. 31 Mar 2025
Deep Track Capital, LP 7.1% +25% $178,290,000 +$38,453,587 3,000,000 +27% Deep Track Capital, LP 30 Sep 2025
MORGAN STANLEY 4.7% $96,628,483 1,943,453 Morgan Stanley 31 Mar 2025
Cowen Financial Products LLC 4.9% $94,926,816 1,909,228 Cowen Financial Products LLC 31 Dec 2024
TANG CAPITAL MANAGEMENT LLC 2.8% -52% $89,776,771 -$95,634,047 1,188,624 -52% TANG CAPITAL MANAGEMENT, LLC 31 Dec 2025

As of 31 Dec 2025, 243 institutional investors reported holding 44,046,610 shares of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS). This represents 104% of the company’s total 42,450,857 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) together control 81% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 8.9% 3,790,557 +0.29% 0.01% $310,370,807
RTW INVESTMENTS, LP 7.9% 3,335,320 +5% 2.7% $273,096,002
Deep Track Capital, LP 7.1% 3,004,034 +0.13% 5.6% $245,970,304
Paradigm Biocapital Advisors LP 6% 2,562,154 -3.9% 5.6% $209,789,170
VANGUARD GROUP INC 5.7% 2,399,560 +5.6% 0% $196,475,972
JENNISON ASSOCIATES LLC 5.3% 2,230,069 -14% 0.11% $182,598,052
MORGAN STANLEY 4.8% 2,040,742 +6.7% 0.01% $167,095,971
JANUS HENDERSON GROUP PLC 4.5% 1,930,325 +34% 0.07% $158,062,427
TANG CAPITAL MANAGEMENT LLC 2.8% 1,188,624 -52% 4.8% $97,324,533
Driehaus Capital Management LLC 2.8% 1,172,427 +14% 0.65% $95,998,323
Assenagon Asset Management S.A. 2.7% 1,127,730 -9.6% 0.14% $92,338,532
Invesco Ltd. 2.4% 1,012,357 +8% 0.01% $82,891,790
GEODE CAPITAL MANAGEMENT, LLC 2.2% 947,763 +0.35% 0% $77,616,160
STATE STREET CORP 2.2% 929,059 -0.76% 0% $76,071,351
LORD, ABBETT & CO. LLC 2% 855,645 -13% 0.21% $70,060,000
BANK OF AMERICA CORP /DE/ 1.8% 758,106 +41% 0% $62,073,719
Frazier Life Sciences Management, L.P. 1.7% 728,644 -38% 1.6% $59,661,371
FMR LLC 1.5% 647,114 +2860% 0% $52,985,671
D. E. Shaw & Co., Inc. 1.4% 615,156 +2.8% 0.04% $50,368,973
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 1.4% 584,686 0% 0.07% $47,874,000
PRICE T ROWE ASSOCIATES INC /MD/ 1.2% 518,780 +15% 0% $42,479,000
TORONTO DOMINION BANK 1.2% 510,253 -17% 0.07% $41,779,516
Clearbridge Investments, LLC 1.2% 506,089 -11% 0.03% $41,438,557
Ensign Peak Advisors, Inc 1.1% 474,050 -1.7% 0.07% $38,815,214
LOOMIS SAYLES & CO L P 1% 441,873 +13% 0.04% $36,180,561

Institutional Holders of Tarsus Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (TARS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 44,046,610 $3,606,025,781 -$100,586,536 $81.88 243
2025 Q3 44,893,892 $2,667,774,204 -$49,024,662 $59.43 219
2025 Q2 46,131,357 $1,868,819,935 +$92,954,236 $40.51 204
2025 Q1 43,564,795 $2,238,109,644 +$155,550,097 $51.37 191
2024 Q4 40,257,261 $2,228,992,305 -$65,425,283 $55.37 192
2024 Q3 43,391,345 $1,426,965,052 +$102,534,235 $32.89 161
2024 Q2 40,066,753 $1,089,006,566 +$6,596,629 $27.18 147
2024 Q1 39,323,641 $1,429,414,516 +$260,798,405 $36.35 155
2023 Q4 32,126,860 $650,570,328 +$49,625,202 $20.25 114
2023 Q3 29,793,106 $529,411,112 +$139,188,159 $17.77 105
2023 Q2 21,435,682 $387,312,097 +$39,178,138 $18.07 92
2023 Q1 20,057,814 $252,130,256 -$6,023,437 $12.57 73
2022 Q4 20,531,051 $300,987,054 +$5,059,618 $14.66 67
2022 Q3 20,489,091 $350,771,070 +$9,266,431 $17.12 72
2022 Q2 19,980,650 $291,715,823 +$98,791,820 $14.60 70
2022 Q1 13,210,299 $222,212,113 -$29,618,514 $16.82 50
2021 Q4 13,072,993 $294,217,317 +$4,316,413 $22.50 43
2021 Q3 12,869,541 $277,366,339 -$12,449,066 $21.55 43
2021 Q2 13,061,656 $378,528,053 +$8,240,890 $28.98 44
2021 Q1 12,761,893 $410,350,129 -$213,790 $32.23 41
2020 Q4 12,759,585 $523,637,183 +$523,637,191 $41.33 39